Galecto, Inc. (GLTO)
Largest Insider Buys in Sector
GLTO Stock Price History Chart
GLTO Stock Performance
About Galecto, Inc.
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 …
Insider Activity of Galecto, Inc.
Over the last 12 months, insiders at Galecto, Inc. have bought $0 and sold $0 worth of Galecto, Inc. stock.
On average, over the past 5 years, insiders at Galecto, Inc. have bought $14.71M and sold $2.42M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $10,750 was made by Schambye Hans T. (Chief Executive Officer) on 2022‑03‑22.
List of Insider Buy and Sell Transactions, Galecto, Inc.
| 2023-08-15 | Sale | 10 percent owner | 822,680 3.5684% | $0.75 | $617,010 | -7.48% | ||
| 2023-07-31 | Sale | 10 percent owner | 209,400 0.8023% | $3.00 | $628,200 | -79.55% | ||
| 2023-07-25 | Sale | 10 percent owner | 39,200 0.1462% | $2.92 | $114,464 | -79.34% | ||
| 2023-07-13 | Sale | 10 percent owner | 194,700 0.7339% | $2.40 | $467,280 | -74.19% | ||
| 2023-04-17 | Sale | 10 percent owner | 12,429 0.0461% | $1.97 | $24,485 | -66.21% | ||
| 2023-04-17 | Sale | 10 percent owner | 13,089 0.0485% | $1.97 | $25,785 | -66.21% | ||
| 2023-04-14 | Sale | 10 percent owner | 39,355 0.1501% | $1.86 | $73,200 | -63.13% | ||
| 2023-04-14 | Sale | 10 percent owner | 41,446 0.158% | $1.86 | $77,090 | -63.13% | ||
| 2023-04-13 | Sale | 10 percent owner | 13,243 0.0519% | $1.82 | $24,102 | -61.26% | ||
| 2023-04-13 | Sale | 10 percent owner | 13,946 0.0546% | $1.82 | $25,382 | -61.26% | ||
| 2023-04-12 | Sale | 10 percent owner | 2,363 0.0093% | $1.81 | $4,277 | -60.83% | ||
| 2023-04-11 | Sale | 10 percent owner | 13,946 0.0543% | $1.82 | $25,382 | -61.41% | ||
| 2023-04-10 | Sale | 10 percent owner | 51,228 0.1984% | $1.79 | $91,698 | -60.81% | ||
| 2023-04-06 | Sale | 10 percent owner | 9,665 0.0396% | $2.00 | $19,330 | -62.87% | ||
| 2023-04-05 | Sale | 10 percent owner | 92,965 0.3672% | $2.18 | $202,664 | -67.11% | ||
| 2022-03-22 | Chief Executive Officer | 5,000 0.0194% | $2.15 | $10,750 | -12.79% | |||
| 2022-03-22 | Chief Medical Officer | 14,604 0.057% | $2.16 | $31,545 | -12.79% | |||
| 2021-12-03 | Chief Financial Officer | 4,000 0.0164% | $2.49 | $9,960 | -16.67% | |||
| 2021-12-03 | General Counsel | 2,000 0.0082% | $2.48 | $4,960 | -16.67% | |||
| 2021-11-09 | Chief Executive Officer | 4,500 0.0178% | $3.50 | $15,750 | -40.86% |
Insider Historical Profitability
| Khuong Chau Quang | 2579657 195.8752% | $5.81 | 1 | 0 | ||
| Novo Holdings A/S | 10 percent owner | 2497791 189.6591% | $5.81 | 1 | 0 | |
| Christgau Stephan | director | 546136 41.4685% | $5.81 | 1 | 0 | |
| ORBIMED ADVISORS LLC | 10 percent owner | 97204 7.3808% | $5.81 | 1 | 15 | |
| Schambye Hans T. | Chief Executive Officer | 52428 3.9809% | $5.81 | 3 | 0 | <0.0001% |
Institutional Investor Ownership
| Novo Holdings A/S | $1.95M | 9.21 | 2.5M | 0% | +$0 | 0.14 | |
| Renaissance Technologies | $452,000.00 | 2.13 | 578,983 | +42.27% | +$134,288.54 | <0.01 | |
| The Vanguard Group | $172,536.00 | 0.82 | 221,200 | 0% | +$0 | <0.0001 | |
| Geode Capital Management | $162,535.00 | 0.77 | 208,333 | 0% | +$0 | <0.0001 | |
| Citadel Advisors LLC | $72,931.00 | 0.35 | 93,501 | +29.09% | +$16,433.09 | <0.0001 |